various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from "sugar control" to both "sugar control" and "heart protection". GLP-1R agonists can improve left ventricular
Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protectionGLP-1Insulin resistanceHeartCardiovascular diseaseDiabetesGlucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family implicated in the control of ...
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab, 2013, 15: 737-749. [11] Smits MM, Muskiet MH, Tonneijck L, et al. Exenatide acutely increases heart rate in parallel with augmented sympathetic ...
( DPP-4) 抑制剂是近年上市的治疗 2 型糖尿病的新型药物.GLP-1 主要通过抑制心肌细胞凋亡,改善内皮细胞功能,减轻体重,降低血 糖,降低血压,改善心肌收缩力,舒张血管等直接或间接发挥其心脏保护作用,GLP-1 受体激动剂和 DPP-4 抑制剂对体重,血压和血脂等心血管危险因素有改善作用.GLP-1 受体激动剂和 DPP-4 ...
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and ...
Long-acting GLP-1 agonists such as GAlbudAb may warrant additional evaluation as novel therapeutic agents to reduce myocardial I/R injury during acute coronary syndrome. 展开 关键词: GLUCAGON-LIKE PEPTIDE-1 ISCHEMIA-REPERFUSION INJURY INCRETIN-BASED THERAPIES CHRONIC HEART-FAILURE CARDIAC-FUNCTION ...
In this study, we aimed to determine whether liraglutide could effectively reduce insulin resistance (IR) by regulating Sestrin2 (SESN2) expression in L6 rat skeletal muscle cells by examining its interactions with SESN2, autophagy, and IR. L6 cells were incubated with liraglutide (10–1000 nM)...
既往二甲双胍是T2DM的一线降糖药物,但是近年来血糖管理重心从“控制血糖”转向“改善心血管和死亡结局,兼顾控制血糖”,同时越来越多的临床研究证实了胰高糖素样肽-1受体激动剂(GLP-1RA)的心血管保护效应,迅速改写了多部权威指南推荐,对传统理念发起挑战。那么如今ASCVD合并T2DM治疗中,GLP-1RA和二甲双胍谁才是真正的...
Heart Failure with Preserved Ejection Fraction (HFpEF) represents a significant challenge in modern cardiovascular medicine, characterized by diastolic dys
Glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor with a broad expression profile across various tissues, including the pancreas, heart, kidneys, blood vessels, liver, central nervous system and lungs [18]. In addition to its primary role in facilitating insulin release...